Six insights on the company’s second-quarter earnings:
1. With $583 million in orthopedic sales abroad, Johnson & Johnson reported total worldwide orthopedic sales revenue of $1.45 billion. This represented a 34.7 percent decrease from the same period in 2019.
2. The company’s hip offerings generated $137 million in U.S. sales and $88 million in international sales, representing year-over-year decreases of 36.5 percent and 39.8 percent, respectively.
3. Johnson & Johnson’s knee business generated $108 million in U.S. sales, down 50.5 percent from $218 million in the second quarter of 2019. International knee sales had an even bigger fall, from $153 million in the second quarter of 2019 to $66 million this most recent quarter.
4. For its “spine, sports and other” business, Johnson & Johnson reported $270 million in U.S. sales and $230 million in international sales, representing respective year-over-year decreases of 45 percent and 29.9 percent.
5. Johnson & Johnson’s trauma business had the lowest year-over-year decline of any line, when compared on worldwide sales. Trauma worldwide sales were down 17.8 percent to $553 million. U.S. sales were down 12.9 percent to $354 million, and international sales decreased 25.2 percent to $198 million.
6. Worldwide medical device sales of $4.3 billion represented a 33.9 percent decline from the second quarter of 2019.
More articles on devices:
7D Surgical radiation-free spine surgery system gets European approval
Medtronic to buy Medicrea for 22% above share price: 6 details
2 hospitals with new spine surgery programs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
